Sanofi, GSK Intend To Supply 200 Mln Doses Of COVID-19 Vaccine To COVAX Facility

(RTTNews) - Sanofi (SNYNF, SNY) and GSK (GSK.L, GSK) have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, under which the companies intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility. The COVAX Facility is part of COVAX, a global collaboration of governments, global health organizations, businesses and philanthropic organizations working to accelerate development, production, and equitable access to COVID-19 vaccines.

Sanofi and GSK initiated a phase 1/2 study on September 3, and anticipate first results in early December 2020, to support the initiation of a pivotal phase 3 study before the end of the year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More